<DOC>
	<DOCNO>NCT01966510</DOCNO>
	<brief_summary>Indication : Patients advance lymphoid malignancy absence HLA identical mismatch donor . Objectives : Overall survival one year . Efficacy &gt; 60 % , rejection rate &lt; 20 % . Inclusion criterion : Age : 18-65 year old , sibling unrelated donor identify , low grade non-hodgkin lymphoma third line ( already receive least one autologous transplantation ) ; hodgkin lymphoma early relapse ( &lt; 1 year ) , receive least one autologous transplantation sensible chemotherapy CLL 17p deletion relapse less 2 year fludarabine nbased regimen relapse one autologous transplantation . Stem cell source : Two cord blood unit contain together 3x107 frozen nucleate cells/Kg 2 6 HLA mismatch patient .</brief_summary>
	<brief_title>Cord Blood Transplantation Patients With Advanced Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age : 1865 year old sibling unrelated donor identify ( 9/10 10/10 ) either one advance lymphoid malignancy 1. low grade nonhodgkin lymphoma third line ( already receive least one autologous transplantation ) 2. hodgkin lymphoma early relapse ( &lt; 1 year ) receive least one autologous transplantation sensible chemotherapy 3 . CLL 17p deletion relapse less 2 year fludarabine nbased regimen relapse one autologous transplantation . No patient sign consent Previous allograft Psychiatric condition HIV positive HVC hepatitis require treatment Previous total body irradiation ( TBI ) Any contraindication TBI Any contraindication allograft , cardiovascular , respiratory , renla liver dysfunction No Health care insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>cord blood transplant</keyword>
	<keyword>advanced lymphoid malignancy</keyword>
</DOC>